Plasma advanced glycation end products are associated with incident cardiovascular events in individuals with type 2 diabetes: a case-cohort study with a median follow-up of 10 years (EPIC-NL)
Although weight loss explains part of this effect, studies suggest the relationship between GLP-1 therapy and improved blood pressure control goes deeper
Patients beginning semaglutide therapy should understand storage protocols and stability markers as part of comprehensive treatment readiness, particularly when genetic factors may influence individual response trajectories
Abstract Depression is a highly prevalent mood disorder and one of the major health concerns in modern society
has served as a consultant or advisory board member for Boehringer Ingelheim, Gilead, Intercept, Merck, Novo Nordisk, Pfizer and ProSciento and as a speaker for Gilead, Intercept, Merck, Novo Nordisk and Pfizer